In addition to CCL5/IFNG expression in the diagnostic tumor biopsy our study also discloses the potential role of serum CCL5 and CXCL9 as early biomarkers of response to neoadjuvant treatment with anti-HER2 antibodies. Here, CXCL9 is linked to neoplasm.